Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
MRSN Mersana Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: MRSN
Price (delayed)
$0.369
Market cap
$45.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.59
Enterprise value
-$31.67M
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives
Highlights
The debt has contracted by 26% YoY and by 14% from the previous quarter
Mersana Therapeutics's EPS has increased by 48% YoY but it has decreased by 5% from the previous quarter
Mersana Therapeutics's net income has increased by 45% YoY but it has decreased by 7% QoQ
MRSN's quick ratio is down by 49% year-on-year and by 19% since the previous quarter
Mersana Therapeutics's revenue has decreased by 16% from the previous quarter and by 11% YoY
Key stats
What are the main financial stats of MRSN
Market
Valuations
Earnings
Shares outstanding
124.63M
Market cap
$45.99M
Enterprise value
-$31.67M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.93
Revenue
$34.01M
Gross profit
$34.01M
Operating income
-$76.85M
Net income
-$74.01M
EBIT
-$69.94M
EBITDA
-$65.21M
Free cash flow
-$79.01M
Per share
Balance sheet
Liquidity
EPS
-$0.59
EPS diluted
-$0.59
Free cash flow per share
-$0.63
Book value per share
-$0.25
Revenue per share
$0.27
TBVPS
$0.9
Total assets
$112.47M
Total liabilities
$143.34M
Debt
$24.62M
Equity
-$30.87M
Working capital
$48.03M
Debt to equity
-0.8
Current ratio
1.83
Quick ratio
1.76
Net debt/EBITDA
1.19
Margins
Efficiency
Dividend
EBITDA margin
-191.8%
Gross margin
100%
Net margin
-217.6%
Operating margin
-226%
Return on assets
-48.9%
Return on equity
N/A
Return on invested capital
-226%
Return on capital employed
-128.8%
Return on sales
-205.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRSN stock price
How has the Mersana Therapeutics stock price performed over time
Intraday
5.79%
1 week
0.85%
1 month
-7.22%
1 year
-83.23%
YTD
-74.2%
QTD
7.21%
Financial performance
How have Mersana Therapeutics's revenue and profit performed over time
Revenue
$34.01M
Gross profit
$34.01M
Operating income
-$76.85M
Net income
-$74.01M
Gross margin
100%
Net margin
-217.6%
The operating income has grown by 46% YoY but it has contracted by 4.8% from the previous quarter
Mersana Therapeutics's net income has increased by 45% YoY but it has decreased by 7% QoQ
The operating margin rose by 39% year-on-year but it has declined by 25% since the previous quarter
The net margin has grown by 38% YoY but it has contracted by 27% from the previous quarter
Price vs fundamentals
How does MRSN's price correlate with its fundamentals
Growth
What is Mersana Therapeutics's growth rate over time
Valuation
What is Mersana Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.93
Mersana Therapeutics's EPS has increased by 48% YoY but it has decreased by 5% from the previous quarter
The stock's P/S is 100% below its 5-year quarterly average of 2654.3 and 74% below its last 4 quarters average of 5.1
Mersana Therapeutics's revenue has decreased by 16% from the previous quarter and by 11% YoY
Efficiency
How efficient is Mersana Therapeutics business performance
The ROIC has plunged by 118% from the previous quarter and by 34% YoY
Mersana Therapeutics's ROS has increased by 40% YoY but it has decreased by 28% from the previous quarter
The ROA is down by 22% since the previous quarter but it is up by 9% year-on-year
Dividends
What is MRSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRSN.
Financial health
How did Mersana Therapeutics financials performed over time
The company's total assets is 22% lower than its total liabilities
MRSN's quick ratio is down by 49% year-on-year and by 19% since the previous quarter
Mersana Therapeutics's current ratio has decreased by 48% YoY and by 16% QoQ
The debt is 180% more than the equity
The company's debt to equity has shrunk by 168% YoY but it has surged by 73% QoQ
The debt has contracted by 26% YoY and by 14% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.